Details of the Drug Combination

General Information of Drug Combination (ID: DCBX6KH)

Drug Combination Name
Exherin Eltanexor oral
Indication
Disease Entry Status REF
Ewing sarcoma Investigative [1]
Component Drugs Exherin   DMC1I56 Eltanexor oral   DM7CLEZ
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: TC-71
Zero Interaction Potency (ZIP) Score: 11.647
Bliss Independence Score: 9.192
Loewe Additivity Score: 3.405
LHighest Single Agent (HSA) Score: 6.878

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Exherin
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Exherin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Neural cadherin (CDH2) TT1WS0T CADH2_HUMAN Binder [4]
------------------------------------------------------------------------------------
Indication(s) of Eltanexor oral
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 1/2 [3]
Myelodysplastic syndrome 2A37 Phase 1/2 [3]
Prostate cancer 2C82.0 Phase 1/2 [3]
Eltanexor oral Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Exportin-1 (XPO1) TTCJUR4 XPO1_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 ClinicalTrials.gov (NCT00264433) A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing soli... Ann Oncol. 2009 Apr;20(4):741-5.